<i>PTEN</i> genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
Sircar Kanishka(The University of Texas MD Anderson Cancer Center), Jeremy A. Squire(Universidade de São Paulo), Guanyong Chen(McGill University Health Centre), Fred Saad(Centre Hospitalier de l’Université de Montréal), Federico A. Monzon(Invitae (United States)), Andrew D. Darnel(Jewish General Hospital), Ismaël Hervé Koumakpayi(Centre Hospitalier de l’Université de Montréal), Maisa Yoshimoto(University of Alberta), Abha Khanna(The University of Texas MD Anderson Cancer Center), Karla Alvarez(Cornell University), Armen Aprikian, Ruth L. Katz(The University of Texas MD Anderson Cancer Center), Tarek A. Bismar(University of Calgary)
Cited by 210
Related Papers
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k